These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8746524)

  • 1. A canine model for determination of the therapeutic index of cytokine inhibitors.
    Sekut L; Han B; Baer P; Verghese MW; Silverstein R; Clifton L; Dennis S; Numerick MJ; Connolly KM
    Lab Anim Sci; 1995 Dec; 45(6):647-51. PubMed ID: 8746524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
    Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
    J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram.
    Ross SE; Williams RO; Mason LJ; Mauri C; Marinova-Mutafchieva L; Malfait AM; Maini RN; Feldmann M
    J Immunol; 1997 Dec; 159(12):6253-9. PubMed ID: 9550429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
    Gantner F; Kupferschmidt R; Schudt C; Wendel A; Hatzelmann A
    Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipopolysaccharide induces expression of tumour necrosis factor alpha in rat brain: inhibition by methylprednisolone and by rolipram.
    Buttini M; Mir A; Appel K; Wiederhold KH; Limonta S; Gebicke-Haerter PJ; Boddeke HW
    Br J Pharmacol; 1997 Dec; 122(7):1483-9. PubMed ID: 9421299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM; Barnes PJ; Giembycz MA
    Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions.
    Barnette MS; Christensen SB; Essayan DM; Grous M; Prabhakar U; Rush JA; Kagey-Sobotka A; Torphy TJ
    J Pharmacol Exp Ther; 1998 Jan; 284(1):420-6. PubMed ID: 9435206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity.
    Aoki M; Kobayashi M; Ishikawa J; Saita Y; Terai Y; Takayama K; Miyata K; Yamada T
    J Pharmacol Exp Ther; 2000 Oct; 295(1):255-60. PubMed ID: 10991987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
    Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
    Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
    Christensen SB; Guider A; Forster CJ; Gleason JG; Bender PE; Karpinski JM; DeWolf WE; Barnette MS; Underwood DC; Griswold DE; Cieslinski LB; Burman M; Bochnowicz S; Osborn RR; Manning CD; Grous M; Hillegas LM; Bartus JO; Ryan MD; Eggleston DS; Haltiwanger RC; Torphy TJ
    J Med Chem; 1998 Mar; 41(6):821-35. PubMed ID: 9526558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock.
    Badger AM; Olivera DL; Esser KM
    Circ Shock; 1994 Dec; 44(4):188-95. PubMed ID: 7628060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of IL-15-stimulated TNF-alpha production by rolipram.
    Kasyapa CS; Stentz CL; Davey MP; Carr DW
    J Immunol; 1999 Sep; 163(5):2836-43. PubMed ID: 10453029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of TNF-alpha production in human mononuclear cells by an adenosine kinase inhibitor.
    Eigler A; Matschke V; Hartmann G; Erhardt S; Boyle D; Firestein GS; Endres S
    J Leukoc Biol; 2000 Jul; 68(1):97-103. PubMed ID: 10914495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of a novel, orally active PDE4 inhibitor.
    Dastidar SG; Ray A; Shirumalla R; Rajagopal D; Chaudhary S; Nanda K; Sharma P; Seth MK; Balachandran S; Gupta N; Palle V
    Pharmacology; 2009; 83(5):275-86. PubMed ID: 19321962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung.
    Gonçalves de Moraes VL; Singer M; Vargaftig BB; Chignard M
    Br J Pharmacol; 1998 Feb; 123(4):631-6. PubMed ID: 9517381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substituted xanthines, pteridinediones, and related compounds as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor alpha.
    Cottam HB; Shih H; Tehrani LR; Wasson DB; Carson DA
    J Med Chem; 1996 Jan; 39(1):2-9. PubMed ID: 8568809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain.
    Hirose R; Manabe H; Nonaka H; Yanagawa K; Akuta K; Sato S; Ohshima E; Ichimura M
    Eur J Pharmacol; 2007 Nov; 573(1-3):93-9. PubMed ID: 17658510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent immunomodulatory effects of acetylsalicylic acid and indomethacin in human whole blood: potential role of cyclooxygenase-2 inhibition.
    Härtel C; von Puttkamer J; Gallner F; Strunk T; Schultz C
    Scand J Immunol; 2004 Oct; 60(4):412-20. PubMed ID: 15379866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of the hypothalamo-pituitary-adrenal axis in the rat by three selective type-4 phosphodiesterase inhibitors: in vitro and in vivo studies.
    Kumari M; Cover PO; Poyser RH; Buckingham JC
    Br J Pharmacol; 1997 Jun; 121(3):459-68. PubMed ID: 9179387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.